Clinical Trials

A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma

Cancer Type

Liver

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Alexander Parikh, MD, MPH, FACS, FSSO

For more information about this study
View Details

About This Study

This is an open-label, single-arm, Phase II feasibility study to examine the proportion of patients that complete neoadjuvant therapy followed by curative-intent surgery. Patients with high-risk, resectable, intrahepatic cholangiocarcinoma will receive the combination of gemcitabine, cisplatin, and durvalumab for 4 cycles in the neoadjuvant setting before undergoing surgical resection. After surgery, patients will receive the combination therapy of gemcitabine, cisplatin, and durvalumab for 4 cycles in the adjuvant setting.